Surgery is slightly more cost-effective than radiotherapy for esophageal cancer in China

A recent study investigated the cost-effectiveness of surgery versus radiotherapy for treating esophageal squamous cell carcinoma (ESCC) in China. Published in Springer Nature on January 30, the research offers a nuanced perspective on treatment strategies for this challenging cancer.

The Challenge of Esophageal Cancer in China

Esophageal cancer is a significant public health concern in China, occurring more frequently there than in many Western nations. The majority of cases in China are ESCC, a type of cancer that presents unique treatment complexities due to variations in each patient’s condition. Doctors must carefully consider surgery, radiotherapy, chemotherapy and immunotherapy, alongside potential side effects and long-term outcomes.

Did You Know? In China, most cases of esophageal cancer are esophageal squamous cell carcinoma (ESCC), while adenocarcinoma is more common in the United States.

Treatment Approaches and Cost Considerations

While numerous studies have examined the cost-effectiveness of drug therapies for esophageal cancer, fewer have directly compared the financial implications of surgery and radiotherapy. What we have is particularly important as both are commonly used treatments with vastly different cost profiles and recovery processes.

In China, healthcare expenses are typically covered through a combination of government insurance, out-of-pocket payments, and private insurance. To provide a comprehensive analysis, researchers utilized a Markov model—a mathematical tool—and real-world data to compare the costs and health benefits associated with each treatment option for ESCC.

Study Details and Findings

Researchers at the Radiotherapy Department of the Fourth Hospital of Hebei Medical University in Shijiazhuang, China, analyzed medical records from 196 patients diagnosed with ESCC. These patients were divided into two groups: 114 who underwent surgery and 82 who received radiotherapy. Both groups also received chemoimmunotherapy before and after their primary treatment.

The analysis revealed that patients in the surgery group experienced longer survival, with a median overall survival of 41.3 months compared to 30.4 months in the radiotherapy group. Progression-free survival was also notably higher in the surgery group, at 28.0 months versus 20.6 months.

Financially, surgery incurred an additional cost of $411,574.32 USD but resulted in a gain of 11.85 quality-adjusted life years (QALYs). This translated to a cost-effectiveness ratio of $34,744.52 USD per QALY. The costs associated with managing adverse events and immunotherapy were identified as key factors influencing cost-effectiveness.

Expert Insight: This study highlights the complex interplay between treatment outcomes and financial considerations in cancer care. While surgery demonstrates improved survival the higher cost requires careful evaluation against established willingness-to-pay thresholds to determine its overall value.

Further analysis indicated that, at willingness-to-pay thresholds ranging from $12,741.11 to $38,223.34 USD per QALY, the probability of surgery being considered cost-effective increased from 10.1% to 62.5%, reaching a total of $33,080.09 USD per QALY.

Looking Ahead

The study provides a real-world assessment of the cost-effectiveness of surgery compared to radiotherapy for ESCC in China. Its strengths lie in its use of a Markov model based on actual patient data and the inclusion of both preoperative and postoperative therapies. However, the retrospective design and reliance on previously published utility values represent limitations.

Future research could benefit from larger, multicenter datasets and consideration of diverse patient characteristics to refine the accuracy of cost-effectiveness estimates. Expanded data collection will reveal further nuances in treatment outcomes and financial impacts. We see also likely that ongoing advancements in both surgical techniques and radiotherapy protocols could shift the cost-effectiveness balance in the future.

Frequently Asked Questions

What type of esophageal cancer was the focus of this study?

The study focused on esophageal squamous cell carcinoma (ESCC), which is the most common type of esophageal cancer in China.

How did researchers determine cost-effectiveness?

Researchers used a Markov model, real-world data, and quality-adjusted life years (QALYs) to compare the costs and health benefits of surgery and radiotherapy.

Did the study find surgery to be definitively more cost-effective?

The study found that surgery was potentially cost-effective depending on willingness-to-pay thresholds, with the probability increasing from 10.1% to 62.5% at certain levels.

Given the complexities of cancer treatment and healthcare economics, how might these findings influence treatment decisions for patients with ESCC in China?